UCI statement on Rahim Emami and UCI Continental Team Pishgaman Cycling
The Union Cycliste Internationale (UCI) announces that it has notified Iranian rider Rahim Emami of an Adverse Analytical Finding (AAF) of Anabolic Androgenic Steroids in a sample collected in the scope of the event Jelajah Malaysia on 18 October 2016.
In accordance with UCI Anti-Doping Rules, the rider has been provisionally suspended until the adjudication of the affair.
This constitutes the second AAF for a member of the UCI Continental Team Pishgaman Cycling (*) within a twelve-month period.
Therefore article 7.12.1 of the UCI Anti-Doping Rules providing for the suspension of the team from 15 days to 45 days (**) will be applied.
The UCI will refer the matter to the Disciplinary Commission which will render a decision in due course.
At this stage of the procedure, the UCI will not comment any further on any of these matters.
(*) On 6 May 2016, the Iranian rider Naser Rezavi, member of the UCI Continental Team Pishgaman Cycling, was notified of an AAF of Anabolic Androgenic Steroids in a sample collected in the scope of the event Jelajah Malaysia on 11 December 2015. Naser Rezavi was sanctioned with a 4 years’ period of ineligibility.
(**) Article 7.12.1 ADR which entered into force on 1 January 2015